Switching From Depot Antipsychotic Drugs to Olanzapine in Patients With Chronic Schizophrenia

Godleski, Linda; Goldsmith, L. Jane; Vieweg, W. Victor R.; Zettwoch, Nancy C; Stikovac, Dejzi; Lewis, Shôn

doi:10.4088/jcp.v64n0203

Cited by 22 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently only little is known about the possible reasons for the positive effects of depot neuroleptics [57]. However, it has been shown in recent studies that depot antipsychotics produce less weight gain in comparison to clozapine and new atypical antipsychotics [58,59]. The other effects of the clinical variables correspond very closet with findings of recent studies [60][61][62].…”

Section: Discussionsupporting

confidence: 74%

The effects of antipsychotic treatment on quality of life of schizophrenic patients under naturalistic treatment conditions: An application of random effect regression models and propensity scores in an observational prospective trial

Kilian

Angermeyer

2005

Qual Life Res

View full text Add to dashboard Cite

The study examines the effect of different types of antipsychotic treatment on the health related quality of life (HRQL) of people with schizophrenia under naturalistic outpatient treatment conditions. In a prospective study design, 307 schizophrenic patients were followed over a period of 2.5 years. HRQL, clinical characteristics, and type of antipsychotic medication were assessed five times every 6 months. HRQL was assessed by the SF-36. Random effect regression models were computed for the SF-36 mental (MCS) and physical (PCS) component scores. Propensity scores were included in the regression models to reduce a possible sample selection bias. Monotherapeutic treatment with new atypical neuroleptic drugs had a more positive effect on the mental health related quality of life (MCS) in comparison to treatment with polypharmacological treatment but not with oral conventional antipsychotics. Monopharmaceutical treatment with depot-antipsychotic drugs had a more positive effect on the physical health related quality of life (PCS) in comparison to polypharmacological treatment. Study results indicate that atypical antipsychotic drugs are not superior to conventional antipsychotics with regard to the effect on QOL. However, monopharmaceutical treatment can be assumed to be more effective in improving mental and physical related QOL than polypharmaceutical treatment.

show abstract

Section: Discussionsupporting

confidence: 74%

The effects of antipsychotic treatment on quality of life of schizophrenic patients under naturalistic treatment conditions: An application of random effect regression models and propensity scores in an observational prospective trial

Kilian

Angermeyer

2005

Qual Life Res

View full text Add to dashboard Cite

show abstract

“…Several studies have evaluated the benefits of switching in between antipsychotic therapy (Godleski et al, 2003;Weiden et al, 2003;Essock et al, 2006). These studies suggest that patients receiving insufficient benefit from antipsychotic therapy often, but not invariably, improve after switching to an alternative agent.…”

Section: Discussionmentioning

confidence: 99%

Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients

Kissling

Glue²,

Medori

et al. 2007

Human Psychopharmacology

View full text Add to dashboard Cite

This subgroup analysis of the 6-month, open-label Switch to Risperidone Microspheres (StoRMi) trial evaluated long-term safety and efficacy of a direct conversion to risperidone long-acting injectable (RLAI) in 52 elderly patients (> or =65 years) with psychosis stabilized on oral or depot antipsychotic. Study outcomes included adverse events, movement disorder severity, psychiatric symptoms, functional ability, quality of life and patient satisfaction. Change in the Positive and Negative Syndrome Scale at endpoint was the primary efficacy measure. The most common dosage of RLAI used at endpoint was 25 mg every 14 days (60%). The trial was completed by 81% of patients, with six patients discontinuing treatment due to an adverse event. Tolerability was good and most side effects were mild to moderate. Serious adverse events occurred in 11 patients. Two of these (suicidal attempt, n = 1; exacerbation of disease, n = 1) were considered possibly related to RLAI. Conversion to RLAI resulted in significant improvements in movement disorder severity, psychiatric symptoms, functional status and patient satisfaction. Mean PANSS total decreased by 15.8 at endpoint, with 23 patients (46.9%) experiencing a > or =20% improvement. This post-hoc analysis supports that RLAI is well tolerated and safe in elderly patients with psychotic illnesses switched from stable antipsychotic regimens, and suggests possible efficacy, although inferences are limited.

show abstract

“…Godleski et al [111] evaluated whether patients stabilized on depot antipsychotic medication could be successfully transitioned to oral olanzapine. The data indicate that oral olanzapine patients demonstrated significant clinical improvement over the depot control group from baseline to 3-month endpoint.…”

Section: Switching Antipsychotic Drugsmentioning

confidence: 99%

Brain-Derived Neurotropic Factor/TrkB Signaling in the Pathogenesis and Novel Pharmacotherapy of Schizophrenia

Pillai¹

2008

Neurosignals

110

View full text Add to dashboard Cite

The role of neurotropins, predominantly brain-derived neurotropic factor (BDNF), has been implicated in the pathophysiology as well as treatment outcome of schizophrenia. Both human and rodent studies indicate that the beneficial effects of antipsychotic drugs are mediated, at least in part, through BDNF and its receptor, TrkB. This review will discuss the available data on the levels of BDNF and TrkB in subjects with schizophrenia and in animals with and without conventional antipsychotics. The data concerning the impact of the antipsychotic drugs on BDNF/TrkB signaling will also be discussed. More importantly, this review will provide future perspective on BDNF/TrkB signaling as a novel molecular target to correct the pathogenesis and improve the long-term clinical outcome by treatments with conventional and adjunctive drugs.

show abstract

Switching From Depot Antipsychotic Drugs to Olanzapine in Patients With Chronic Schizophrenia

Cited by 22 publications

References 0 publications

The effects of antipsychotic treatment on quality of life of schizophrenic patients under naturalistic treatment conditions: An application of random effect regression models and propensity scores in an observational prospective trial

The effects of antipsychotic treatment on quality of life of schizophrenic patients under naturalistic treatment conditions: An application of random effect regression models and propensity scores in an observational prospective trial

Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients

Brain-Derived Neurotropic Factor/TrkB Signaling in the Pathogenesis and Novel Pharmacotherapy of Schizophrenia

Contact Info

Product

Resources

About